PCSK9 inhibition in patients with heart transplantation: A case series
- 1 September 2019
- journal article
- research article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 13 (5) , 721-724
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Proprotein convertase subtilisin/kexin type 9Current Opinion in Cardiology, 2018
- Long-term efficacy and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibodies: A meta-analysis of 11 randomized controlled trialsJournal of Clinical Lipidology, 2018
- A safety evaluation of evolocumabExpert Opinion on Drug Safety, 2017
- Pooled Safety Analysis of Evolocumab in Over 6000 Patients From Double-Blind and Open-Label Extension StudiesCirculation, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trialsScientific Reports, 2017
- Hyperlipidaemia in immunosuppressionCurrent Opinion in Lipidology, 2016
- Statin therapy in cardiac allograft vasculopathy progression in heart transplant patients: Does potency matter?Transplantation Reviews, 2016
- The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathwayAtherosclerosis, 2013
- Standardized Cardiovascular Data for Clinical Research, Registries, and Patient CareJACC, 2013